Telix Pharmaceuticals Ltd
About Telix Pharmaceuticals Ltd
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $3.2B
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.2B
- Dividend yield
- 1.48%
- Shares outstanding
- 333.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 13, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 47% below its 52-week high.
- Pays a dividend yielding about 1.48% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Telix Pharmaceuticals Ltd.
Write a review
News about Telix Pharmaceuticals Ltd
News & sentiment via Polygon.io
